In multiple myeloma (MM) an increase in circulating lymphocytes expressing plasma cell-associated antigens (PCAA) has been described. Its prognostic significance was evaluated in this study. The immunologic phenotype of peripheral blood lymphocytes was analyzed with a panel of monoclonal antibodies specific for B, T, natural killer lymphocytes, and PCAA (CD38, PCAl ) in 5 2 MM patients at diagnosis, remission, and during relapse, 18 monoclonal gammopathy of undetermined significance (MGUS), and 25 normal controls. No significant phenotypic alteration was observed in MGUS. In MM. the number of B lymphocytes was in the normal range at diagnosis and during the subsequent phases. A CD4lCD8 ratio decrease, during N MULTIPLE MYELOMA (MM), phenotypic and I functional alterations of several lymphocyte subsets have been described. Anti-idiotypic antibodies specific for each patient have been used to detect circulating tumor cells, and they seem to represent the entire spectrum of the B-cell differentiation pathway in peripheral Kubagawa et a12 has identified circulating pre-B lymphocytes belonging to the tumor clone, and King and Nelson3 have described tumor cells coexpressing lymphocyte and plasma cell antigens. Molecular analysis has corroborated these findings: lymphocytes with the same immunoglobulin (Ig) gene rearrangement as bone marrow myeloma cells have been rep~rted.'.~ Moreover, a correlation between clinical progression and the number of circulating neoplastic cells has been suggested. ' Phenotypic alterations in T-cell subsets, such as a decreased CD4/CD8 ratio'.' and an increased number of activated T cells, expressing the CD74 (HLA-DR) have been also described.' T cells seem unable to mediate normal cytotoxic and LAK activities.".' Moreover, these alterations are more evident in patients with active MM.
I functional alterations of several lymphocyte subsets have been described. Anti-idiotypic antibodies specific for each patient have been used to detect circulating tumor cells, and they seem to represent the entire spectrum of the B-cell differentiation pathway in peripheral Kubagawa et a12 has identified circulating pre-B lymphocytes belonging to the tumor clone, and King and Nelson3 have described tumor cells coexpressing lymphocyte and plasma cell antigens. Molecular analysis has corroborated these findings: lymphocytes with the same immunoglobulin (Ig) gene rearrangement as bone marrow myeloma cells have been rep~rted.'.~ Moreover, a correlation between clinical progression and the number of circulating neoplastic cells has been suggested. ' Phenotypic alterations in T-cell subsets, such as a decreased CD4/CD8 ratio'.' and an increased number of activated T cells, expressing the CD74 (HLA-DR) have been also described.' T cells seem unable to mediate normal cytotoxic and LAK activities.".' Moreover, these alterations are more evident in patients with active MM.
A significant increase in circulating lymphocytes expressing plasma cell-associated antigens (PCAA), such as CD38 or PCA1, has also been It is well-known that these antigens are expressed by both terminally differentiated B lymphocytes and other hematopoietic cells, such as activated T 1ymph0cytes.l~ A two-color analysis has illustrated the expression of PCAA by B and T cells.12 This increase of both B neoplastic cells and activated T cells is considered a marker of poor progn~sis.'.~ In a preliminary study, both of these cell subsets, detected by the analysis of PCAA expression, were significantly higher in M M than in monoclonal gammopathy of undetermined significance (MGUS), and in MM in remission phase than in relapse phase.I2
In the present study the immunologic phenotype of 52 M M patients in different phases of the disease and 18 MGUS was evaluated. Moreover, a survival analysis was performed to assess the prognostic significance of the expression of PCAA by circulating lymphocytes. Patients were treated with 12 courses of melphalan and prednisone or alternating VMCP/VBAP in a previous report we showed that these regimens were equally effective even in high-risk patients."
The 25 normal controls were healthy subjects comparable for mean age and sex distribution with our patient population, and screened for platelet aggregation.
A total of 135 phenotypic analyses of peripheral blood lymphocytes (PBL) were performed. In the 32 MM patients evaluated at diagnosis the analysis was also performed in remission and relapse (Table 1) .
PBL were separated on Lymphoprep (Nyegaard, Oslo, Norway) gradient, and monocytes were removed by adherence on plastic culture flasks (Falcon, Becton Dickinson, Mountain View, CA) at 37OC for 60 minutes. In double-layer staining, lymphocytes were For personal use only. on November 15, 2017. by guest www.bloodjournal.org From incubated for 30 minutes at 4OC with 5 pL of monoclonal antibody (MoAb), washed twice, and then incubated for 30 minutes with 2.5 pL of FITC-conjugated goat antimouse Igs. At least 5,000 cells were scored using a Facscan (Becton Dickinson). B1 (CD20), B4 (CD19), and PCAl were purchased from Coulter Clone (Luton, England); Leu 4 (CD3), Leu3 (CD4), Leu2 (CD8), transferrin receptor (CD71), CALLA (CDlO), Leu15 (CDI lb), HLA-DR (CD74), LEU7 (CD57), and fluorescein-conjugated goat antimouse Ig from Becton Dickinson; and HAN-PC1 (CD38) was kindly provided by Dr K. Thielemans (Vrije Universiteit Brussel, Brussels, Belgium).
Results are expressed as absolute number per liter. Quantile-quantile plots were used to assess the normality of the data.20 Because the majority of data sets were not normally distributed, data were summarized as median (range). The KruskalWallis test was used'' to simultaneously compare the expression of each lymphocyte antigen analyzed in five subgroups: controls, MGUS, MM at diagnosis, remission, and relapse. If statistically significant, comparisons between pairs of interest were performed with the Wilcoxon test. The pairs of interest were: normal control versus MGUS, MGUS versus MM at diagnosis, MM at diagnosis versus MM at relapse, and MM at remission versus MM at relapse. Because of the large number of tests run (4 x 13 = 52), the increased risk of significant results obtained just by chance was tapered by Bonferroni's correction.2' Therefore, the significance level of P value was set to ,001. The Kaplan-Meier method was used to estimate survival, and the log-rank test to compare survival^.^^,^^ Correlation analysis was performed using Pearson's test. All data were processed with the SAS statistical software package (SAS Institute Inc, Cary, NC).
Statistical analysis.

RESULTS
PBL immunologic phenotypes of the 52 MM, 18 MGUS patients, and the 25 controls are shown in Table 2 .
In MGUS patients no phenotypic alteration was detected. In M M patients, no significant phenotypic variation was present in the B-cell compartment (CD19, CD20) both at diagnosis or during remission and relapse. The number of T cells detected by the expression of CD3 was in the normal range, whereas the CD4/CD8 ratio decreased during the course of the disease due to both a progressive increase in CD8+ and a constant low value in CD4+ lymphocytes. These data, together with the high expression of CDllb+ and CD74+ lymphocytes, point to the elevation of activated suppressor cells, as previously demonstrated.' The transferrin receptor (CD71), another activation marker, was also higher in M M at diagnosis than in MGUS and normal controls, normal during remission, and high during relapse. CD10+ lymphocytes sharply increased during relapse in four patients only, suggesting an intrinsic individual patient characteristic rather than a general feature. The natural killer subset, identified by the CD57, showed no significant variation at diagnosis and during follow-up.
In the 32 M M patients evaluated at diagnosis, a significant increase of CD38+ lymphocytes was detected in comparison with MGUS ( Table 2) . Among M M patients, CD38+ lymphocytes were significantly increased during relapse. Similar variations were observed for PCAl expression, but they did not reach the statistical significance using Bonferroni's correction ( Table 2) . A statistically significant correlation was detected between the number of CD38+ and PCAl + lymphocytes ( r = .71; P < .0001), suggesting their partial coexpression by the same cell; this was confirmed by a two-color analysis in five patients (data not shown). Figure 1 shows the distribution of CD38+ lymphocytes in normal controls, in MGUS, and in M M during different phases of the disease.
To assess the prognostic value of PCAA expression, a survival analysis was performed in 32 M M patients evalu- Clinical characteristics of the two groups of patients separated according to this CD38 cutoff are described in Table 3 .
Median survival of patients with CD38+ lymphocytes greater than 0.45 x 109/L was 14 months, whereas patients with lower values did not reach the median survival at 32 months (P < .0007) (Fig 2) .
It may be stressed that all data are presented as the absolute number of circulating lymphocytes. Even more significant results were obtained on considering the percentage of positive lymphocytes, particularly in the case of CD38 and PCAl expression. MM patients displayed a significant lymphocytopenia in comparison with normal controls (median 1,561 v 2,073; P < .0001). An increase in the percentage of lymphocytes carrying PCAA resulted in subset unbalance and was frequently not evident when absolute numbers were considered. 
0
DISCUSSION
Alterations of the immunologic phenotype of virtually all PBL subsets have been reported in MM.7-'0.'2.'3325 This report shows that the number of circulating lymphocytes carrying PCAA'2.'3 is related to the course of the disease: values were higher during relapse. Moreover, a survival analysis showed that the number of PCAA' lymphocytes at diagnosis is a useful prognostic parameter because median survival for patients with a high number was significantly reduced.
The immunologic phenotype of 52 MM patients and 18 MGUS was evaluated with a panel of MoAbs. No significant variation in the B-lymphocyte compartment was shown by the B4 (CD19) and B1 (CD20) MoAbs. A reduction in CD4+ and an increase in CD8' lymphocytes were particularly evident during relapse, leading to the previously described reduction of the CD4/CD8 ratio.7s8 Investigation of 
